EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis

Kenichi Kimura, Hisashi Narita, Hissei Imai, Hisashi Akiyama, Shuhei Ishikawa, Ryo Sawagashira, Tomoyuki Isoyama, Mariko Nohara, Michiyo Kawamura, Yukari Kono, Takuya Saito, Ichiro Kusumi

Frontiers in Psychiatry · 22.09.2023 · 14

DOI: 10.3389/fpsyt.2023.1248397 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Psychiatry, online erschienen am 22.09.2023. Verfasst von Kenichi Kimura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurology, Hokkaido University Hospital, Sapporo, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the anticipated efficacy of escitalopram in treating depression and anxiety in individuals with preexisting cardiovascular conditions, persistent concerns regarding its adverse effects have emerged. In this systematic review, we aimed to evaluate the cardiovascular safety profile of escitalopram compared with that of placebo in patients with underlying cardiovascular disease.

Methods

We used a predefined search strategy in PubMed, Cochrane Central Register of Controlled Trials, Embase, International Clinical Trials Registry Platform, and ClinicalTrials.gov to identify studies evaluating adverse cardiovascular reactions to escitalopram in patients with underlying cardiovascular disease. Randomized controlled trials (RCTs) that provided results on cardiovascular safety outcomes were included. Two independent reviewers screened the abstracts and full texts of the individual studies. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach.

Results

The primary outcomes were the frequency of major adverse cardiovascular events (MACE), QTc prolongation, and discontinuation of study medication. We identified 5 RCTs with 773 participants who met the inclusion criteria. Escitalopram was not associated with significantly increased risk of MACE (risk ratio [RR] = 1.85; 95% confidence interval [CI] 0.80 to 4.26; I 2 0%; 5 RCTs; n = 773, moderate certainty of evidence), discontinuation of study medication (RR = 1.03; 95% CI 0.84–1.26; I 2 0%; 5 RCTs; n = 773, low certainty of evidence), and QTc prolongation (RR = 1.20; 95% CI 0.76–1.90; I 2 0%; 4 RCTs; n = 646, low certainty of evidence).

Conclusion

Escitalopram does not significantly increase the risk of cardiovascular adverse reactions compared with placebo in patients with underlying cardiovascular disease. However, the presence of wide CIs and the limited number of included studies highlight the need for further studies with larger sample sizes to enhance the precision and reliability of these findings.

Systematic review registration

International Prospective Register of Systematic Reviews [CRD42022298181].

Schlagwörter

Stichwörter der Autor:innen

cardiovascular diseaseescitaloprammajor adverse cardiovascular eventsmeta-analysissystematic review

Autor:innen und Institutionen

  • Department of Psychiatry and Neurology, Hokkaido University Hospital, Sapporo, Japan.
  • Department of Health Promotion and Human Behavior, Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan.
  • Department of Physiology, Hokkaido University School of Medicine, Sapporo, Japan.
  • Creative Research Institute, Hokkaido University, Sapporo, Japan.
  • Medical Sciences Group, Research Support Division, Hokkaido University Library, Sapporo, Japan.
  • Department of Child and Adolescent Psychiatry, Hokkaido University Hospital, Sapporo, Japan.

Zitieren

APA

Kimura, K., Narita, H., Imai, H., Akiyama, H., Ishikawa, S., Sawagashira, R., Isoyama, T., Nohara, M., Kawamura, M., Kono, Y., Saito, T., & Kusumi, I. (2023). Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1248397

Vancouver

Kimura K, Narita H, Imai H, Akiyama H, Ishikawa S, Sawagashira R, et al. Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1248397

BibTeX
@article{Kimura2023,
  author = {Kimura, Kenichi and Narita, Hisashi and Imai, Hissei and Akiyama, Hisashi and Ishikawa, Shuhei and Sawagashira, Ryo and Isoyama, Tomoyuki and Nohara, Mariko and Kawamura, Michiyo and Kono, Yukari and Saito, Takuya and Kusumi, Ichiro},
  title = {Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis},
  journal = {Frontiers in Psychiatry},
  year = {2023},
  volume = {14},
  doi = {10.3389/fpsyt.2023.1248397}
}
Kostenlos starten →